LONDON, July 09, 2026 /PRNewswire/ – Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company’s ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion.
Key highlights:
- Commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets, with exclusivity subject to agreed minimum purchase and performance requirements.
- Supports near-term potential revenue opportunities through purchase-order-driven supply of Virax’s commercially available ImmuneSelect product line
- Provides access to Fosun Diagnostics’ established regional commercial infrastructure and customer network.
- Framework supports expansion into additional products, higher-volume supply arrangements and potential OEM/private-label opportunities.
- Near-term commercial opportunity separate from ViraxImmune™, the Company’s in-development diagnostic platform.
